Sing Chor-Wing, Wong Ian C K, Cheung Bernard M Y, Chan Johnny C Y, Chu Jody K P, Cheung Ching-Lung
Department of Pharmacology and Pharmacy, The University of Hong Kong, Hong Kong.
Centre for Safe Medication Practice and Research, Department of Pharmacology and Pharmacy, The University of Hong Kong, Hong Kong.
Pharmacoepidemiol Drug Saf. 2017 Mar;26(3):248-255. doi: 10.1002/pds.4156. Epub 2017 Jan 13.
Drug-induced agranulocytosis is a rare but life-threatening adverse drug reaction. Its epidemiology in Chinese is largely unknown. This study aimed to estimate the incidence, mortality, and risk of the drugs associated with agranulocytosis in Hong Kong Chinese.
A population-based case-control study was conducted using the Clinical Data Analysis and Reporting System, a database managed by the Hong Kong Hospital Authority. Patients with drug-induced agranulocytosis from 1 January 2004 to 31 December 2013 were identified. World Health Organization causality assessment was used to evaluate the possible drug aetiology of each case. Odd ratios (ORs) of the drug exposure were calculated using exact conditional logistic regression.
A total of 155 cases of drug-induced agranulocytosis were identified. Mean age was 51.4 years, and 95 cases were female. Incidence rate was estimated to be 2.2 cases per million person-years, and the all-cause mortality of patients with drug-induced agranulocytosis was 3.9%. Among the cases, the most common associated drug groups were antithyroid drugs (41.9%), antimicrobials (20%), anticonvulsants (10.3%), and antipsychotics (6.5%). Carbimazole had the highest risk of agranulocytosis (adjusted OR 416.7, 95% confidence interval (CI) 51.5-3372.9) with an incidence of 9.2 (95%CI 6.9-12.1) per 10 000 users and 3.6 (95%CI 2.7-4.8) per 10 000 user-years. Other drugs with significant risk included cephalosporins, clozapine, penicillins, phenytoin, and propyl thiouracil.
The incidence and mortality in Hong Kong Chinese were relatively low compared to Caucasians. Antithyroid drugs were the most common implicated drug class, and carbimazole had the highest risk of agranulocytosis. Copyright © 2017 John Wiley & Sons, Ltd.
药物性粒细胞缺乏症是一种罕见但危及生命的药物不良反应。其在中国的流行病学情况在很大程度上尚不明确。本研究旨在估算香港华人中与粒细胞缺乏症相关药物的发病率、死亡率及风险。
采用香港医院管理局管理的临床数据分析与报告系统进行一项基于人群的病例对照研究。确定2004年1月1日至2013年12月31日期间药物性粒细胞缺乏症患者。使用世界卫生组织因果关系评估来评估每个病例可能的药物病因。使用精确条件逻辑回归计算药物暴露的比值比(OR)。
共确定155例药物性粒细胞缺乏症病例。平均年龄为51.4岁,95例为女性。发病率估计为每百万人年2.2例,药物性粒细胞缺乏症患者的全因死亡率为3.9%。在这些病例中,最常见的相关药物类别为抗甲状腺药物(41.9%)、抗菌药物(20%)、抗惊厥药物(10.3%)和抗精神病药物(6.5%)。卡比马唑导致粒细胞缺乏症的风险最高(调整后OR为416.7,95%置信区间(CI)为51.5 - 3372.9),每10000名使用者中的发病率为9.2(95%CI为6.9 - 12.1),每10000名使用者年发病率为3.6(95%CI为2.7 - 4.8)。其他具有显著风险的药物包括头孢菌素、氯氮平、青霉素、苯妥英和丙硫氧嘧啶。
与高加索人相比,香港华人的发病率和死亡率相对较低。抗甲状腺药物是最常涉及的药物类别,卡比马唑导致粒细胞缺乏症的风险最高。版权所有© 2017约翰·威利父子有限公司。